Advertisement

Antiallergika

  • Anette Zawinell
  • Ulrich Schwabe

Zusammenfassung

Größte Gruppe der Antiallergika sind die Hyposensibilisierungsmittel zur allergenspezifischen Immuntherapie bei allergisch bedingten Atemwegskrankheiten. Danach folgen H1-Antihistaminika, die vor allem zur Behandlung des Heuschnupfens, der allergischen Bindehautentzündung und der Urtikaria eingesetzt werden.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Arzneimittelkommission der deutschen Ärzteschaft (2007): Stellungnahme der AkdÄ zur allergenspezifischen Immuntherapie.Google Scholar
  2. Dtsch Ärztebl 104: A 3355–3357Google Scholar
  3. Abramson M, Puy R, Weiner J (2003): Allergen immunotherapy for asthma (Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Oxford: Update SoftwareGoogle Scholar
  4. Adkinson NF, Eggleston PA, Eney D, Goldstein EO, Schuberth KC et al (1997) A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med 336:324–331PubMedCrossRefGoogle Scholar
  5. Arvidsson MB, Löwhagen O, Rak S (2002) Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy. J Allergy Clin Immunol 109:777–783PubMedCrossRefGoogle Scholar
  6. Aust W, Wichmann G, Dietz A (2010) Therapiekontrolle der Insektengifthyposensibilisierung. Laryngorhinootologie 89:725–728PubMedCrossRefGoogle Scholar
  7. Austen KF (2001) Allergies, anaphylaxis, and systemic mastocytosis. In: Braunwald E et al (eds) Harrison's principles of internal medicine. McGraw-Hill Medical Publishing Division, New York, pp 1913–1922Google Scholar
  8. Bousquet J, Hejjaoui A, Clauzel AM, Guerin B, Dhivert H, Skassa-Brociek W, Wichel FB (1988) Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. II. Prediction of efficacy of immunotherapy. J Allergy Clin Immunol 82:971–977PubMedCrossRefGoogle Scholar
  9. Bousquet J, Scheinmann P, Guinnepain MT, Perrin-Fayolle M, Sauvaget J, Tonnel AB et al (1999) Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. Allergy 54:249–260PubMedCrossRefGoogle Scholar
  10. Bundesministerin für Gesundheit (2008): Verordnung über die Ausdehnung der Vorschriften über die Zulassung der Arzneimittel auf Therapieallergene, die für einzelne Personen auf Grund einer Rezeptur hergestellt werden, sowie über Verfahrensregelungen der staatlichen Chargenprüfung (Therapieallergene-Verordnung) vom 7. November 2008. Bundesgesetzblatt 2008 Teil I Nr. 51, Bonn 13. November 2008, Seite 2177–2178. Internet: www.bgbl.de/Xaver/start.xav?startbk=Bundesanzeiger_BGBlGoogle Scholar
  11. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S (2007) Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007 Jan 24(1):CD00193–6Google Scholar
  12. Dahl R, Kapp A, Colombo G, de Monchy JG, Rak S, Emminger W, Rivas MF, Ribel M, Durham SR (2006) Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 118:434–440PubMedCrossRefGoogle Scholar
  13. Dahl R, Kapp A, Colombo G, de Monchy JG, Rak S, Emminger W, Riis B, Grønager PM, Durham SR (2008) Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol 121:512–518PubMedCrossRefGoogle Scholar
  14. Deutsche GA, klinische I (2009): Die spezifische Immuntherapie (Hyposensibilisierung) bei IgE-vermittelten allergischen Erkrankungen. Allergo J 18: 508–537. Internet: http://dgaki.de/wp-content/uploads/2010/05/Leitlinie_SIT2009.pdf.
  15. Didier A, Malling HJ, Worm M, Horak F, Jäger S, Montagut A, Andre C, Beaumont O de, Melac M (2007) Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grasspollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 120:1338–1345PubMedCrossRefGoogle Scholar
  16. Durham SR (2008) Sublingual immunotherapy: what have we learnt from the ‚big trials’? Curr Opin Allergy Clin Immunol 8:577–584PubMedCrossRefGoogle Scholar
  17. Durham SR, Walker SM, Varga EM, Jacobson MR, O’Brian F, Noble W et al (1999) Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 341:468–475PubMedCrossRefGoogle Scholar
  18. Golden DB (2005) Insect sting allergy and venom immunotherapy: a model and a mystery. J Allergy Clin Immunol 115:439–447PubMedCrossRefGoogle Scholar
  19. Guez S, Vatrinet C, Fadel R, Andre C (2000) House-dust-mite sublingual-swallow immunotherapy (SLIT) in perennial rhinitis: a double-blind, placebo-controlled study. Allergy 55:369–375PubMedCrossRefGoogle Scholar
  20. Hoff M, Krail M, Kästner M, Haustein D, Vieths S (2002) Fusarium culmorum causes strong degradation of pollen allergens in extract mixtures. J Allergy Clin Immunol 109:96–101PubMedCrossRefGoogle Scholar
  21. Lin SY, Erekosima N, Kim JM, Ramanathan M, Suarez-Cuervo C, Chelladurai Y, Ward D, Segal JB (2013) Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. JAMA 309:1278–1288PubMedCrossRefGoogle Scholar
  22. Lüderitz-Püchel U, Keller-Stanislawski B, Haustein D (2001): Neubewertung des Risikos von Test- und Therapieallergenen. Eine Analyse der UAW-Meldungen von 1991 bis 2000. Bundesgesunheitsbl – Gesundheitsforsch – Gesundheitsschutz 44: 709–718Google Scholar
  23. Maurer M, Rosén K, Hsieh HJ, Saini S, Grattan C, Gimenéz-Arnau A, Agarwal S, Doyle R, Canvin J, Kaplan A, Casale T (2013) Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 368:924–935PubMedCrossRefGoogle Scholar
  24. Mellerup MT, Hahn GW, Poulsen LK, Malling HJ (2000) Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment. Clin Exp Allergy 30:1423–1429PubMedCrossRefGoogle Scholar
  25. Möller C, Dreborg S, Ferdousi HA, Halken S, Høst A, Jacobsen L et al (2002) Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-Study). J Allergy Clin Immunol 109:251–256PubMedCrossRefGoogle Scholar
  26. Moffitt JE, Golden DB, Reisman RE, Lee R, Nicklas R, Freeman T, deshazo R, Tracy J, Bernstein IL, Blessing-Moore J, Khan DA, Lang DM, Portnoy JM, Schuller DE, Spector SL, Tilles SA (2004) Stinging insect hypersensitivity: a practice parameter update. J Allergy Clin Immunol 114:869–886PubMedCrossRefGoogle Scholar
  27. Nelson HS (2007) Allergen immunotherapy: where is it now? J Allergy Clin Immunol 119:769–779PubMedCrossRefGoogle Scholar
  28. Olsen OT, Larsen KR, Jacobsan L, Svedsen UG (1997) A 1-year placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults. Allergy 52:853–859PubMedCrossRefGoogle Scholar
  29. O’Neill SM, Forsyth A (1988) Urticaria. Prescribers J 28:14–20Google Scholar
  30. Petersen BN, Janniche H, Munch EP, Wihl JA, Bowadt H, Ipsen H, Lowenstein H (1988) Immunotherapy with partially purified and standardized tree pollen extracts. I. Clinical results from a three-year double-blind study of patients treated with pollen extracts either of birch or combinations of alder, birch and hazel. Allergy 43:353–362PubMedCrossRefGoogle Scholar
  31. Pfaar O, Jung K, Wolf H, Decot E, Kleine-Tebbe J, Klimek L, Wüstenberg E (2012) Immunological effects and tolerability of a new fast updosed immunologically enhanced subcutaneous immunotherapy formulation with optimized allergen/adjuvant ratio. Allergy 67:630–637PubMedCrossRefGoogle Scholar
  32. Pichler CE, Helbling A, Pichler WJ (2001) Three years of specific immunotherapy with housedust- mite extracts in patients with rhinitis and asthma: significant improvement of allergen- specific parameters and of nonspecific bronchial hyperreactivity. Allergy 56: 301–306 Pichler CE, Marquardsen A, Sparholt S, Lowenstein H, Bircher A, Bischof M, Pichler WJ (1997): Specific immunotherapy with Dermatophagoides ptheronyssinus and D. farinae results in decreased bronchial hyperreactivity. Allergy 52:274–283CrossRefGoogle Scholar
  33. Radulovic S, Wilson D, Calderon M, Durham S (2011) Systematic reviews of sublingual immunotherapy (SLIT). Allergy 66:740–752PubMedCrossRefGoogle Scholar
  34. Rietschel E, Hutegger I, Lange L, Urbanek R (2013) Anaphylaxie – Diagnostisches und therapeutisches Vorgehen. Med Klin Intensivmed Notfmed 108:239–249PubMedCrossRefGoogle Scholar
  35. Ring J, Fuchs T, Schultze-Werninghaus G (Hrsg) (2004) DGAI, ÄDA, DAAU: Weißbuch Allergie in Deutschland, 2. Aufl. Urban und Vogel MünchenGoogle Scholar
  36. Routledge PA, Lindquist M, Edwards IR (1999) Spontaneous reporting of suspected adverse reactions to antihistamines: a national and international perspective. Clin Exp Allergy 29(Suppl 3):240–246PubMedCrossRefGoogle Scholar
  37. Ruëff F, Wenderoth A, Przybilla B (2001) Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol 108:1027–1032PubMedCrossRefGoogle Scholar
  38. Sennekamp J, Fuchs Th, Hornung B, Kersten W, Klimek L, Leupold W, Merk H, Rebien W, Schultze-Werninghaus G (2002) Empfehlungen zur praktischen Durchführung der spezifischen Immuntherapie mit Allergenen. Allergo J 11:332–338Google Scholar
  39. Simons FE, Simons KJ (2011) Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol 128:1139–1150PubMedCrossRefGoogle Scholar
  40. Valsecchi R, di Landro A, Pansera B, Cainelli T (1994) Contact dermatitis from a gel containing dimethindene maleate. Contact Dermat 30:248–249Google Scholar
  41. WHO Position Paper (1998) Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 53(Suppl 1):1–42Google Scholar
  42. Wilson DR, Torres-Lima M, Durham SR (2010) Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2010 Dec 8(12):CD00289–3Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Anette Zawinell
    • 1
  • Ulrich Schwabe
    • 2
  1. 1.Wissenschaftliches InstitutAOKBerlin
  2. 2.Pharmakologisches InstitutUniversität HeidelbergHeidelberg

Personalised recommendations